The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Marlex Pharmaceuticals Inc. to supply ezetimibe tablets. The single award contract has a potential value of $14.2 million with a period of performance from April 2024 through April 2025 and four one-year option periods. Delivery orders will provide approximately 29,326 bottles of 30 count tablets, 153,548 bottles of 90 count tablets, and 98,519 bottles of 500 count tablets annually to the VA, DOD, BOP and IHS through the VA and DOD pharmaceutical prime vendor programs.
The originating pre-solicitation notice indicated the VA National Acquisition Center's intent to competitively solicit offers for a one year contract plus four option years to supply ezetimibe 10mg tablets. The solicitation was released on November 28, 2023 with a response due date of December 12, 2023 and no set aside designation. The estimated annual requirements were outlined as 29,326 bottles of 30 count tablets, 153,548 bottles of 90 count tablets, and 98,519 bottles of 500 count tablets to support VA, DOD, BOP and IHS healthcare programs. Marlex Pharmaceuticals will supply the contracted ezetimibe tablets from its place of performance in New Castle, Delaware.
Generated 2/9/24, 9:23 AM